PT - JOURNAL ARTICLE AU - ŠTEFAN KEČKÉŠ AU - JÚLIUS PALAJ AU - IVETA WACZULÍKOVÁ AU - DANIEL DYTTERT AU - EMÍLIA MOJTOVÁ AU - GUSTÁV KOVÁČ AU - ŠTEFAN DURDÍK TI - Pretreatment Levels of Chromogranin A and Neuron-specific Enolase in Patients With Gastroenteropancreatic Neuroendocrine Neoplasia AID - 10.21873/invivo.12574 DP - 2021 Sep 01 TA - In Vivo PG - 2863--2868 VI - 35 IP - 5 4099 - http://iv.iiarjournals.org/content/35/5/2863.short 4100 - http://iv.iiarjournals.org/content/35/5/2863.full SO - In Vivo2021 Sep 01; 35 AB - Background/Aim: Chromogranin A (CgA) and neuron-specific enolase (NSE) are applied in the diagnosis of neuroendocrine neoplasms (NENs), especially non-functional ones. The aim of this study was to investigate the predictive values of CgA and NSE in long-term survival. Patients and Methods: Our retrospective analysis included 65 patients with histologically verified gastroenteropancreatic NEN between 2005 and 2019. We performed bivariate and multivariable analyses to evaluate the relationship between CgA and NSE values before histological assessment and overall survival. Distribution of time-to-event was analyzed using Kaplan-Meier survival curves and modelled by Cox regression models. Results: Elevated NSE levels prior to histology were significantly associated with worse survival (HR=1.13, p=0.004) and were associated with low-differentiated NENs (rs=0.321, p=0.0338). CgA was associated with well-differentiated tumors (rs=0.233), but not significantly. Conclusion: Pretreatment serum levels of NSE can serve as a valuable additional predictor of long-term survival in patients with NEN.